NEW YORK, Feb 22 - Celera’s Chinese subsidiary Shanghai GeneCore Biotechnologies and Macrogen of South Korea have penned an agreement to jointly develop a SNP database, The Korea Times said Wednesday.
Macrogen, which offers custom sequencing services and has developed DNA chips as well as a set of customized transgenic mice, is currently exploring SNP patterns in the Korean population as part of its effort to branch into personalized medicine.
“In the long-term, we are hoping to cash on our genetic SNP databases, '' The Korean Times cited Suh Jung-seon, president of Macrogen,as saying.
A Celera spokeswoman was not immediately available to discuss the terms or the structure of the deal.
Shanghai GeneCore, a genomics service company that specializes in nucleotide synthesis, DNA sequencing, bioinformatics analysis, and mutation detection, also has genome research collaborations with more than 1,000 biotech research centers, hospitals, and pharmaceutical companies in China.
Celera Genomics and its sister company Applied Biosystems each own a 47.5 percent stake in Shanghai GeneCore. The company, which was founded in 1997 by three companies, including Applied Biosystems, has on going research collaborations with several Chinese government agencies and research institutes. Celera Genomics bought its stake in the company last January.
In addition to its relationship with Shanghai GeneCore, Celera is reported to have other partnerships in Asia. According to previous press reports, Celera is a major investor in Asia Celera Biotechnology, a joint venture with Taiwan’s President Enterprises and Ho Tung Chemical.